Yttrium-90 and Rhenium-188 Radiopharmaceuticals for Radionuclide Therapy

In-111 pentetreotide Tc-99m tin colloid Y-90 DOTATATE
FIG. 10.14. Anterior planar images of uptake by 111 In pentetreotide, 99m Tc tin colloid and
90 Y DOTATATE in the same patient.
Anterior scintigraphy carried out using the somatostatin analogue
111 In pentetreotide, 99m Tc tin colloid and bremsstrahlung radiation after the
administration of therapeutic doses of 90 Y DOTATATE were performed in the
same patients (see Fig. 10.14) and showed the following information: (i) high
accumulation of pentetreotide visible in the middle region corresponded to the
primary tumours in the pancreas (carcinoid), and smaller surrounding areas
were associated with metastases in the liver and retroperitoneal lymph nodes;
(ii) areas in the liver showed less accumulation of radiocolloids corresponding to
metastases; and (iii) high accumulations of the therapeutic radiopharmaceutical
were localized in the primary tumours of the pancreas, with moderate
accumulation owing to metastases in the liver.
10.3.4.3. Conclusion
Radiopharmaceuticals for clinical use for PRRT in Serbia could be provided
by using the proposed methodology. Despite insufficient data, beneficial effects
on the clinical symptoms, hormone production and tumour proliferation were
found without major clinical side effects. Thus, the first results in clinical
application of these radiopharmaceuticals have shown that treatment with
90 Y DOTATATE is a feasible method and could be useful for the management of
patients with inoperable or disseminated neuroendocrine tumours.
10.4. DEVELOPMENT OF 90 SR/ 90 Y GENERATOR SYSTEMS
A 90 Sr/ 90 Y generator was developed to meet the demand of therapeutic
applications in radiopharmaceutical research. An electrochemical method was
198